82 related articles for article (PubMed ID: 3045725)
21. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
22. Prolactin levels and bromocriptine treatment of short luteal phase.
Lehtovirta P; Arjomaa P; Ranta T; Laatikainen T; Hirvonen E; Seppälä M
Int J Fertil; 1979; 24(1):57-60. PubMed ID: 37181
[TBL] [Abstract][Full Text] [Related]
23. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
Parsanezhad ME; Alborzi S; Jahromi BN
Int J Fertil Womens Med; 2002; 47(6):272-7. PubMed ID: 12570169
[TBL] [Abstract][Full Text] [Related]
24. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
25. [Cancers of the breast at metastatic high-risk: prediction of survival by steroidal receptors].
Mauriac L; Durand M; Chauvergne J; David M; Wafflart J
Bull Cancer; 1989; 76(1):33-41. PubMed ID: 2713513
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
27. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine for treatment of benign breast disease. A double-blind clinical trial versus placebo.
Parlati E; Polinari U; Salvi G; Giorlandino C; Liberale I; Fiorella G; Dell'Acqua S
Acta Obstet Gynecol Scand; 1987; 66(6):483-8. PubMed ID: 3321867
[TBL] [Abstract][Full Text] [Related]
29. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.
Lee MS; Song HC; An H; Yang J; Ko YH; Jung IK; Joe SH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):19-27. PubMed ID: 19968833
[TBL] [Abstract][Full Text] [Related]
30. Prolactin levels in infertility and bromocriptine therapy in hyperprolactinaemia.
Prathibha D; Govardhani M; Krishna PT
J Indian Med Assoc; 1994 Dec; 92(12):397-9. PubMed ID: 7876578
[TBL] [Abstract][Full Text] [Related]
31. Treatment of benign breast disease with bromocriptine.
Mussa A; Dogliotti L
J Endocrinol Invest; 1979; 2(1):87-91. PubMed ID: 489922
[TBL] [Abstract][Full Text] [Related]
32. Clinical trial of 2-bromo-alpha-ergocryptine (NSC-169774) in human prostatic cancer.
Coune A; Smith P
Cancer Chemother Rep; 1975; 59(1):209-13. PubMed ID: 1093667
[TBL] [Abstract][Full Text] [Related]
33. Effect of bromocriptine on affect and libido in hyperprolactinemia.
Koppelman MC; Parry BL; Hamilton JA; Alagna SW; Loriaux DL
Am J Psychiatry; 1987 Aug; 144(8):1037-41. PubMed ID: 3300375
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.
Kopp A; Jonat W; Schmahl M; Knabbe C
Cancer Res; 1995 Oct; 55(20):4512-5. PubMed ID: 7553618
[TBL] [Abstract][Full Text] [Related]
36. A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviour.
Messina G; Lissoni P; Brivio F; Rovelli F; Fumagalli L; Bartolacelli E; Mazza U; Colombo E; Bertoglio A
In Vivo; 2008; 22(6):845-8. PubMed ID: 19181018
[TBL] [Abstract][Full Text] [Related]
37. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604
[TBL] [Abstract][Full Text] [Related]
38. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
[TBL] [Abstract][Full Text] [Related]
39. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of hyperprolactinemia and acromegaly with lisuride].
Berezin M; Elchalal U; Olchovsky D
Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
